These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement. Caravatto PP; Cohen R Curr Atheroscler Rep; 2017 Oct; 19(11):45. PubMed ID: 28986720 [TBL] [Abstract][Full Text] [Related]
46. Simultaneous living donor liver transplant with sleeve gastrectomy for metabolic syndrome and NASH-related ESLD-First report from India. Kumar S; Khandelwal N; Kumar A; Yadav K; Sharma S; Sable S; Chauhan A; Kapoor S; Varma V; Palep J; Kumaran V Indian J Gastroenterol; 2017 May; 36(3):243-247. PubMed ID: 28560633 [TBL] [Abstract][Full Text] [Related]
47. [What is the position of bariatric surgery in the treatment of non-alcoholic steatohepatitis?]. NtandjaWandji LC; Baud G; Lassailly G Presse Med; 2019 Dec; 48(12):1502-1506. PubMed ID: 31757736 [TBL] [Abstract][Full Text] [Related]
48. Treatment options for nonalcoholic steatohepatitis - a safety evaluation. Issa D; Wattacheril J; Sanyal AJ Expert Opin Drug Saf; 2017 Aug; 16(8):903-913. PubMed ID: 28641031 [TBL] [Abstract][Full Text] [Related]
49. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Cernea S; Cahn A; Raz I Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774 [TBL] [Abstract][Full Text] [Related]
50. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Caldwell S Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529 [TBL] [Abstract][Full Text] [Related]
52. A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. Cusi K Liver Int; 2020 Feb; 40 Suppl 1():82-88. PubMed ID: 32077613 [TBL] [Abstract][Full Text] [Related]
53. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J; Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270 [TBL] [Abstract][Full Text] [Related]
57. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019 [TBL] [Abstract][Full Text] [Related]
58. Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery. Seki Y; Kakizaki S; Horiguchi N; Hashizume H; Tojima H; Yamazaki Y; Sato K; Kusano M; Yamada M; Kasama K J Gastroenterol; 2016 Mar; 51(3):281-9. PubMed ID: 26314837 [TBL] [Abstract][Full Text] [Related]
59. The molecular basis for current targets of NASH therapies. Qureshi K; Neuschwander-Tetri BA Expert Opin Investig Drugs; 2020 Feb; 29(2):151-161. PubMed ID: 31847612 [No Abstract] [Full Text] [Related]
60. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ; J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]